Journal Articles Conference Presentations Book Chapters Public Presentations

Update on gene therapy for cystic fibrosis.

Griesenbach U, Geddes DM, Alton EW

Current Opinion In Molecular Therapeutics

Curr Opin Mol Ther. 2003 Oct;5(5):489-94.

Print this page

Cystic fibrosis (CF) is a monogenic autosomal recessive disease. Although several organs are affected, severe lung disease is the cause of most morbidity and mortality in CF individuals. The first clinical trials in CF patients were carried out in 1993, and to date, 29 trial protocols have been published. Although proof-of-principle for gene transfer to the lung has been established, efficiency is generally low. Steady progress has been made over the last two years and key papers, including recent advances in viral and nonviral gene transfer agents, will be reviewed here.

Go Back to Publications     View on Pubmed (14601517)    View on Google Scholar


 

Other Publications by these authors
Lung clearance index in primary ciliary dyskinesia and bronchiectasis.
Irving SJ et al. American Journal Of Respiratory And Critical Care Medicine (2014) Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
Alton EW et al. Gene Therapy (2013) The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
Alton EW et al. Biomaterials (2013) Self-reactive CFTR T cells in humans: implications for gene therapy.
Calcedo R et al. Human Gene Therapy. Clinical Development (2013) A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
Alton EW et al. Thorax (2013) Expert opinion in biological therapy: update on developments in lung gene transfer.
Griesenbach U et al. Expert Opinion On Biological Therapy (2013)